Guggenheim Capital LLC Alkermes Plc. Transaction History
Guggenheim Capital LLC
- $12.3 Billion
- Q2 2025
A detailed history of Guggenheim Capital LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 8,869 shares of ALKS stock, worth $242,655. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,869
Previous 52,356
83.06%
Holding current value
$242,655
Previous $1.73 Million
85.36%
% of portfolio
0.0%
Previous 0.02%
Shares
27 transactions
Others Institutions Holding ALKS
# of Institutions
400Shares Held
176MCall Options Held
564KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$796 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$506 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$275 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$225 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$175 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.49B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...